These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 16787204)
21. The Recent Development of α7 Nicotinic Acetylcholine Receptor (nAChR) Ligands as Therapeutic Candidates for the Treatment of Central Nervous System (CNS) Diseases. Beinat C; Banister SD; Herrera M; Kassiou M Curr Pharm Des; 2016; 22(14):2134-51. PubMed ID: 26818858 [TBL] [Abstract][Full Text] [Related]
22. α7 and β2 Nicotinic Acetylcholine Receptor Subunits Form Heteromeric Receptor Complexes that Are Expressed in the Human Cortex and Display Distinct Pharmacological Properties. Thomsen MS; Zwart R; Ursu D; Jensen MM; Pinborg LH; Gilmour G; Wu J; Sher E; Mikkelsen JD PLoS One; 2015; 10(6):e0130572. PubMed ID: 26086615 [TBL] [Abstract][Full Text] [Related]
23. Relating neuronal nicotinic acetylcholine receptor subtypes defined by subunit composition and channel function. Nai Q; McIntosh JM; Margiotta JF Mol Pharmacol; 2003 Feb; 63(2):311-24. PubMed ID: 12527802 [TBL] [Abstract][Full Text] [Related]
24. Positive allosteric modulation of the alpha7 nicotinic acetylcholine receptor: ligand interactions with distinct binding sites and evidence for a prominent role of the M2-M3 segment. Bertrand D; Bertrand S; Cassar S; Gubbins E; Li J; Gopalakrishnan M Mol Pharmacol; 2008 Nov; 74(5):1407-16. PubMed ID: 18678621 [TBL] [Abstract][Full Text] [Related]
25. Targeting alpha7 nicotinic acetylcholine receptors in the treatment of schizophrenia. Hajós M; Rogers BN Curr Pharm Des; 2010; 16(5):538-54. PubMed ID: 19909231 [TBL] [Abstract][Full Text] [Related]
26. Stimulation of nicotinic acetylcholine alpha7 receptors rescue schizophrenia-like cognitive impairments in rats. Potasiewicz A; Nikiforuk A; Hołuj M; Popik P J Psychopharmacol; 2017 Feb; 31(2):260-271. PubMed ID: 28168926 [TBL] [Abstract][Full Text] [Related]
27. Positive allosteric modulators of α7* or β2* nicotinic acetylcholine receptors trigger different kinase pathways in mitochondria. Uspenska K; Lykhmus O; Arias HR; Pons S; Maskos U; Komisarenko S; Skok M Int J Biochem Cell Biol; 2018 Jun; 99():226-235. PubMed ID: 29704624 [TBL] [Abstract][Full Text] [Related]
29. A silent agonist of α7 nicotinic acetylcholine receptors modulates inflammation ex vivo and attenuates EAE. Godin JR; Roy P; Quadri M; Bagdas D; Toma W; Narendrula-Kotha R; Kishta OA; Damaj MI; Horenstein NA; Papke RL; Simard AR Brain Behav Immun; 2020 Jul; 87():286-300. PubMed ID: 31874200 [TBL] [Abstract][Full Text] [Related]
30. Targeting α4β2 nicotinic acetylcholine receptors in central nervous system disorders: perspectives on positive allosteric modulation as a therapeutic approach. Grupe M; Grunnet M; Bastlund JF; Jensen AA Basic Clin Pharmacol Toxicol; 2015 Mar; 116(3):187-200. PubMed ID: 25441336 [TBL] [Abstract][Full Text] [Related]
31. Biomolecular recognition of antagonists by α7 nicotinic acetylcholine receptor: Antagonistic mechanism and structure-activity relationships studies. Peng W; Ding F Eur J Pharm Sci; 2015 Aug; 76():119-32. PubMed ID: 25963024 [TBL] [Abstract][Full Text] [Related]
32. Aminobenzisoxazole compounds as agonists of α7 nicotinic acetylcholine receptors: a patent evaluation (WO 2017027600). He Y; Shen J Expert Opin Ther Pat; 2018 May; 28(5):429-436. PubMed ID: 29566578 [TBL] [Abstract][Full Text] [Related]
33. Repeated administration of alpha7 nicotinic acetylcholine receptor (nAChR) agonists, but not positive allosteric modulators, increases alpha7 nAChR levels in the brain. Christensen DZ; Mikkelsen JD; Hansen HH; Thomsen MS J Neurochem; 2010 Aug; 114(4):1205-16. PubMed ID: 20533993 [TBL] [Abstract][Full Text] [Related]
35. In vitro pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107. Malysz J; Anderson DJ; Grønlien JH; Ji J; Bunnelle WH; Håkerud M; Thorin-Hagene K; Ween H; Helfrich R; Hu M; Gubbins E; Gopalakrishnan S; Puttfarcken PS; Briggs CA; Li J; Meyer MD; Dyhring T; Ahring PK; Nielsen EØ; Peters D; Timmermann DB; Gopalakrishnan M J Pharmacol Exp Ther; 2010 Sep; 334(3):863-74. PubMed ID: 20504915 [TBL] [Abstract][Full Text] [Related]
36. Distinct profiles of alpha7 nAChR positive allosteric modulation revealed by structurally diverse chemotypes. Grønlien JH; Håkerud M; Ween H; Thorin-Hagene K; Briggs CA; Gopalakrishnan M; Malysz J Mol Pharmacol; 2007 Sep; 72(3):715-24. PubMed ID: 17565004 [TBL] [Abstract][Full Text] [Related]
37. Novel approaches to study the involvement of α7-nAChR in human diseases. Palma E; Conti L; Roseti C; Limatola C Curr Drug Targets; 2012 May; 13(5):579-86. PubMed ID: 22300023 [TBL] [Abstract][Full Text] [Related]
38. In Vitro and In Vivo Characterization of Dibenzothiophene Derivatives [ Donat CK; Hansen HH; Hansen HD; Mease RC; Horti AG; Pomper MG; L'Estrade ET; Herth MM; Peters D; Knudsen GM; Mikkelsen JD Molecules; 2020 Mar; 25(6):. PubMed ID: 32245032 [TBL] [Abstract][Full Text] [Related]
39. Counteracting desensitization of human α7-nicotinic acetylcholine receptors with bispyridinium compounds as an approach against organophosphorus poisoning. Scheffel C; Niessen KV; Rappenglück S; Wanner KT; Thiermann H; Worek F; Seeger T Toxicol Lett; 2018 Sep; 293():149-156. PubMed ID: 29248576 [TBL] [Abstract][Full Text] [Related]